Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Craig L. Slingluff,Hassane M. Zarour,Michael A. Postow,Philip Friedlander,Craig E. Devoe,Kelly Smith,Donna H. Deacon,Mary J. Macri,Aileen Ryan,Ralph Venhaus,Jedd D. Wolchok

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）

引用 0|浏览23

暂无评分

摘要

e15175Background: IPI is an approved immunotherapy for advanced melanoma; it has enhanced spontaneous immunity to NY-ESO-1, a cancer-testis antigen expressed by some melanomas. NY-ESO-1 vaccines ha...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要